{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:32:05Z","timestamp":1794468725872,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["413657723"],"award-info":[{"award-number":["413657723"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["74031971-TRR 240"],"award-info":[{"award-number":["74031971-TRR 240"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["413657723"],"award-info":[{"award-number":["413657723"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia\/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional\/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Focal cerebral ischemia was induced in C57Bl\/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24\u00a0h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome\u2014even when administered with a delay of 1\u00a0day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-022-02674-w","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:04:11Z","timestamp":1672815851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice"],"prefix":"10.1186","volume":"20","author":[{"given":"Maximilian","family":"Bellut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N. R.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Schuhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"issue":"5","key":"2674_CR1","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/STROKEAHA.108.534503","volume":"40","author":"M Gelderblom","year":"2009","unstructured":"Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40(5):1849\u201357.","journal-title":"Stroke"},{"key":"2674_CR2","doi-asserted-by":"crossref","unstructured":"Stoll G, Schuhmann MK, Nieswandt B, Kollikowski AM, Pham M. An intravascular perspective on hyper-acute neutrophil, T-cell and platelet responses: similarities between human and experimental stroke. J Cereb Blood Flow Metab. 2022;0271678X2211057.","DOI":"10.1177\/0271678X221105764"},{"key":"2674_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100270","volume":"15","author":"MK Schuhmann","year":"2021","unstructured":"Schuhmann MK, Kollikowski AM, M\u00e4rz AG, Bieber M, Pham M, Stoll G. Danger-associated molecular patterns are locally released during occlusion in hyper-acute stroke. Brain Behav Immunity Health. 2021;15: 100270.","journal-title":"Brain Behav Immunity Health"},{"issue":"3","key":"2674_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12975-021-00938-w","volume":"13","author":"AM Kollikowski","year":"2022","unstructured":"Kollikowski AM, Pham M, M\u00e4rz AG, Papp L, Nieswandt B, Stoll G, et al. Platelet activation and chemokine release are related to local neutrophil-dominant inflammation during hyperacute human stroke. Transl Stroke Res. 2022;13(3):364\u20139. https:\/\/doi.org\/10.1007\/s12975-021-00938-w.","journal-title":"Transl Stroke Res."},{"issue":"2","key":"2674_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1523\/JNEUROSCI.2439-14.2015","volume":"35","author":"A Liesz","year":"2015","unstructured":"Liesz A, Dalpke A, Mracsko E, Roth S, Zhou W, Yang H, et al. DAMP signaling is a key pathway inducing immune modulation after brain injury. J Neurosci. 2015;35(2):583\u201398.","journal-title":"J Neurosci"},{"issue":"6","key":"2674_CR6","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI135530","volume":"130","author":"C Iadecola","year":"2020","unstructured":"Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Investig. 2020;130(6):2777\u201388.","journal-title":"J Clin Investig"},{"issue":"11","key":"2674_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S1474-4422(19)30078-X","volume":"18","author":"K Shi","year":"2019","unstructured":"Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke. Lancet Neurol. 2019;18(11):1058\u201366.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2674_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12974-019-1571-8","volume":"16","author":"S Dabrowska","year":"2019","unstructured":"Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflamm. 2019;16(1):178.","journal-title":"J Neuroinflamm"},{"issue":"7","key":"2674_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JPY. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677\u201387.","journal-title":"Nat Med"},{"issue":"8","key":"2674_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"2674_CR11","doi-asserted-by":"crossref","unstructured":"Franke M, Bieber M, Kraft P, Weber ANR, Stoll G, Schuhmann MK. The NLRP3 inflammasome drives inflammation in ischemia\/reperfusion injury after transient middle cerebral artery occlusion in mice. Brain Behav Immunity. 2020. S0889159120324521.","DOI":"10.1016\/j.bbi.2020.12.009"},{"issue":"1","key":"2674_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-021-04379-z","volume":"13","author":"M Bellut","year":"2021","unstructured":"Bellut M, Papp L, Bieber M, Kraft P, Stoll G, Schuhmann MK. NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood\u2013brain barrier integrity in murine stroke. Cell Death Dis. 2021;13(1):20.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2674_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbrc.2016.12.161","volume":"483","author":"P Murthy","year":"2017","unstructured":"Murthy P, Durco F, Miller-Ocuin JL, Takedai T, Shankar S, Liang X, et al. The NLRP3 inflammasome and bruton\u2019s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. Biochem Biophys Res Commun. 2017;483(1):230\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2674_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/1747493019841242","volume":"14","author":"M Alishahi","year":"2019","unstructured":"Alishahi M, Farzaneh M, Ghaedrahmati F, Nejabatdoust A, Sarkaki A, Khoshnam SE. NLRP3 inflammasome in ischemic stroke: as possible therapeutic target. Int J Stroke. 2019;14(6):574\u201391.","journal-title":"Int J Stroke"},{"issue":"6","key":"2674_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12975-018-0666-3","volume":"9","author":"S Chen","year":"2018","unstructured":"Chen S, Mei S, Luo Y, Wu H, Zhang J, Zhu J. Gasdermin family: a promising therapeutic target for stroke. Transl Stroke Res. 2018;9(6):555\u201363.","journal-title":"Transl Stroke Res"},{"issue":"3","key":"2674_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20052458","volume":"203","author":"C Kleinschnitz","year":"2006","unstructured":"Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513\u20138.","journal-title":"J Exp Med"},{"key":"2674_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cellimm.2017.06.003","volume":"318","author":"HA Seifert","year":"2017","unstructured":"Seifert HA, Benedek G, Liang J, Nguyen H, Kent G, Vandenbark AA, et al. Sex differences in regulatory cells in experimental stroke. Cell Immunol. 2017;318:49\u201354.","journal-title":"Cell Immunol"},{"issue":"1","key":"2674_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12974-017-0792-y","volume":"14","author":"MK Schuhmann","year":"2017","unstructured":"Schuhmann MK, Guthmann J, Stoll G, Nieswandt B, Kraft P, Kleinschnitz C. Blocking of platelet glycoprotein receptor Ib reduces \u201cthrombo-inflammation\u201d in mice with acute ischemic stroke. J Neuroinflamm. 2017;14(1):18.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"2674_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-021-02095-1","volume":"18","author":"MK Schuhmann","year":"2021","unstructured":"Schuhmann MK, Bieber M, Franke M, Kollikowski AM, Stegner D, Heinze KG, et al. Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice. J Neuroinflamm. 2021;18(1):46.","journal-title":"J Neuroinflamm"},{"issue":"3","key":"2674_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/01.STR.17.3.472","volume":"17","author":"JB Bederson","year":"1986","unstructured":"Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472\u20136.","journal-title":"Stroke"},{"issue":"8","key":"2674_CR21","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/ijms20082019","volume":"20","author":"MK Schuhmann","year":"2019","unstructured":"Schuhmann MK, Kraft P, Bieber M, Kollikowski AM, Schulze H, Nieswandt B, et al. Targeting platelet GPVI Plus rt-PA administration but not \u03b12\u03b21-mediated collagen binding protects against ischemic brain damage in mice. IJMS. 2019;20(8):2019.","journal-title":"IJMS"},{"issue":"4","key":"2674_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/01.STR.32.4.1005","volume":"32","author":"J Chen","year":"2001","unstructured":"Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32(4):1005\u201311.","journal-title":"Stroke"},{"issue":"4","key":"2674_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.nurx.2006.08.001","volume":"3","author":"T Schallert","year":"2006","unstructured":"Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx. 2006;3(4):497\u2013504.","journal-title":"NeuroRx"},{"issue":"4","key":"2674_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"1","key":"2674_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/mps4010023","volume":"4","author":"M Franke","year":"2021","unstructured":"Franke M, Bieber M, Stoll G, Schuhmann MK. Validity and efficacy of methods to define blood brain barrier integrity in experimental ischemic strokes: a comparison of albumin western blot, IgG Western blot and albumin immunofluorescence. MPS. 2021;4(1):23.","journal-title":"MPS"},{"issue":"1","key":"2674_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12974-017-0890-x","volume":"14","author":"MK Schuhmann","year":"2017","unstructured":"Schuhmann MK, Langhauser F, Kraft P, Kleinschnitz C. B cells do not have a major pathophysiologic role in acute ischemic stroke in mice. J Neuroinflamm. 2017;14(1):112.","journal-title":"J Neuroinflamm"},{"issue":"10029","key":"2674_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","volume":"387","author":"M Goyal","year":"2016","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723\u201331.","journal-title":"Lancet"},{"issue":"11","key":"2674_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41582-020-00417-0","volume":"16","author":"G Stoll","year":"2020","unstructured":"Stoll G, Pham M. Beyond recanalization\u2014a call for action in acute stroke. Nat Rev Neurol. 2020;16(11):591\u20132.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2674_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nm.1999","volume":"15","author":"T Shichita","year":"2009","unstructured":"Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17\u2013producing \u03b3\u03b4T cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15(8):946\u201350.","journal-title":"Nat Med"},{"key":"2674_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa9853","author":"G Llovera","year":"2015","unstructured":"Llovera G, Hofmann K, Roth S, Salas-P\u00e9rdomo A, Ferrer-Ferrer M, Perego C, et al. Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aaa9853.","journal-title":"Sci Transl Med."},{"issue":"8","key":"2674_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41582-019-0221-1","volume":"15","author":"G Stoll","year":"2019","unstructured":"Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke\u2014implications for treatment. Nat Rev Neurol. 2019;15(8):473\u201381.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2674_CR32","doi-asserted-by":"publisher","first-page":"22887","DOI":"10.1038\/s41598-021-02360-6","volume":"11","author":"V G\u00f6b","year":"2021","unstructured":"G\u00f6b V, Voll MG, Zimmermann L, Hemmen K, Stoll G, Nieswandt B, et al. Infarct growth precedes cerebral thrombosis following experimental stroke in mice. Sci Rep. 2021;11(1):22887.","journal-title":"Sci Rep"},{"issue":"9","key":"2674_CR33","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.1038\/cddis.2013.326","volume":"4","author":"D Yang-Wei Fann","year":"2013","unstructured":"Yang-Wei Fann D, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 2013;4(9):e790\u2013e790.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2674_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/jcbfm.2013.242","volume":"34","author":"F Yang","year":"2014","unstructured":"Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab. 2014;34(4):660\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"2674_CR35","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","volume":"6","author":"M Ito","year":"2015","unstructured":"Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, et al. Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6(1):7360.","journal-title":"Nat Commun"},{"issue":"13","key":"2674_CR36","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1073\/pnas.1419090112","volume":"112","author":"A Denes","year":"2015","unstructured":"Denes A, Coutts G, L\u00e9n\u00e1rt N, Cruickshank SM, Pelegrin P, Skinner J, et al. AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc Natl Acad Sci USA. 2015;112(13):4050\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2674_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/STROKEAHA.118.023620","volume":"50","author":"E Lemarchand","year":"2019","unstructured":"Lemarchand E, Barrington J, Chenery A, Haley M, Coutts G, Allen JE, et al. Extent of ischemic brain injury after thrombotic stroke is independent of the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome. Stroke. 2019;50(5):1232\u20139.","journal-title":"Stroke"},{"issue":"10","key":"2674_CR38","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1093\/rheumatology\/keac273","volume":"61","author":"ANR Weber","year":"2022","unstructured":"Weber ANR, Tapia-Abell\u00e1n A, Liu X, Dickh\u00f6fer S, Ar\u00f3stegui JI, Pelegr\u00edn P, et al. Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950\/CRID3. Rheumatology. 2022;61(10):e299\u2013313. https:\/\/doi.org\/10.1093\/rheumatology\/keac273.","journal-title":"Rheumatology."},{"issue":"4","key":"2674_CR39","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/jcbfm.2010.220","volume":"31","author":"C Kilkenny","year":"2011","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments\u2014the ARRIVE Guidelines. J Cereb Blood Flow Metab. 2011;31(4):991\u20133.","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-022-02674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-022-02674-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-022-02674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:04:53Z","timestamp":1672815893000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-022-02674-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2674"],"URL":"https:\/\/doi.org\/10.1186\/s12974-022-02674-w","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by local governmental authorities (Regierung von Unterfranken), and conducted in accordance with the US National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Moreover, the experiments were designed, performed, and reported according to the Animal Research Reporting of In Vivo Experiments (ARRIVE) guidelines [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}